- Conditions
- Pediatrics, Muscle Spasticity, Cerebral Palsy, Stroke
- Interventions
- Botulinum Toxin Type A
- Biological
- Lead sponsor
- Allergan
- Industry
- Eligibility
- 2 Years to 17 Years
- Enrollment
- 220 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2018
- U.S. locations
- 24
- States / cities
- Pasadena, California • Pomona, California • San Diego, California + 19 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1297–1320
of 7,459
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Blinded CGM, real-time CGM
- Device
- Lead sponsor
- Jaeb Center for Health Research
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 166 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 6
- States / cities
- Aurora, Colorado • Atlanta, Georgia • Baltimore, Maryland + 3 more
- Conditions
- Congenital Fibrinogen Deficiency
- Interventions
- FCH
- Biological
- Lead sponsor
- CSL Behring
- Industry
- Eligibility
- Not listed
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 3
- States / cities
- Aurora, Colorado • Las Vegas, Nevada • Durham, North Carolina
- Conditions
- Non-Alcoholic Steatohepatitis (NASH)
- Interventions
- GFT505 80mg, GFT505 120mg, Placebo
- Drug
- Lead sponsor
- Genfit
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 275 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 19
- States / cities
- Fresno, California • La Jolla, California • Aurora, Colorado + 15 more
- Conditions
- Status Epilepticus
- Interventions
- lorazepam or diazepam
- Drug
- Lead sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
- NIH
- Eligibility
- 3 Months to 18 Years
- Enrollment
- 259 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 12
- States / cities
- Davis, California • Aurora, Colorado • Washington D.C., District of Columbia + 9 more
- Conditions
- ANCA Associated Vasculitis (AAV)
- Interventions
- Rapcabtagene autoleucel, Active Comparator, Glucocorticoids
- Biological · Other · Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 126 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 14
- States / cities
- Aurora, Colorado • Jacksonville, Florida • Chicago, Illinois + 10 more
- Conditions
- Metastatic Colorectal Adenocarcinoma
- Interventions
- Trastuzumab, Tucatinib
- Drug
- Lead sponsor
- Seagen Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 117 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 41
- States / cities
- Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 34 more
- Conditions
- Locally Advanced Unresectable Primary Central Chondrosarcoma, Metastatic Primary Central Chondrosarcoma, Unresectable Primary Central Chondrosarcoma
- Interventions
- Belinostat, Biopsy Procedure, Biospecimen Collection, Computed Tomography, Decitabine and Cedazuridine, Guadecitabine, Magnetic Resonance Imaging
- Drug · Procedure
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 39
- States / cities
- Phoenix, Arizona • Duarte, California • Los Angeles, California + 32 more
- Conditions
- Postpartum
- Interventions
- Offer of Participant's Choice of Contraception Method
- Other
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 15 Years to 35 Years · Female only
- Enrollment
- 208 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Gastroparesis, Diabetes Mellitus
- Interventions
- Placebo, Relamorelin
- Drug
- Lead sponsor
- Allergan
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 336 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 113
- States / cities
- Birmingham, Alabama • Dothan, Alabama • Huntsville, Alabama + 95 more
- Conditions
- Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Squamous Cell Carcinoma, Not Otherwise Specified, Stage IB Cervical Cancer AJCC v6 and v7, Stage IIA Cervical Cancer AJCC v7, Stage IIB Cervical Cancer AJCC v6 and v7, Stage IIIB Cervical Cancer AJCC v6 and v7, Stage IVA Cervical Cancer AJCC v6 and v7
- Interventions
- Brachytherapy, Carboplatin, Cisplatin, External Beam Radiation Therapy, Paclitaxel, Quality-of-Life Assessment
- Radiation · Drug · Other
- Lead sponsor
- GOG Foundation
- Network
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 926 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2021
- U.S. locations
- 315
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 220 more
- Conditions
- Miscellaneous Neoplasm, Nos, Non-Neoplastic Condition, Nos
- Interventions
- Telemedicine, Genetic Testing, Internet-Based Intervention, Educational Intervention, Patient Navigation, Interview, Survey Administration
- Other · Behavioral
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 535 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2029
- U.S. locations
- 327
- States / cities
- Anchorage, Alaska • Fairbanks, Alaska • Phoenix, Arizona + 238 more
- Conditions
- HIV Infections
- Interventions
- Lamivudine
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 12 Years and older
- Enrollment
- 210 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Ends 1998
- U.S. locations
- 39
- States / cities
- Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 27 more
- Conditions
- Head and Neck Cancer, Dysphagia
- Interventions
- non- head and neck self reporting, head neck self reporting, provider reporting
- Other
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years to 100 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 6
- States / cities
- Scottsdale, Arizona • Aurora, Colorado • Rochester, Minnesota + 3 more
- Conditions
- Autism Spectrum Disorder
- Interventions
- Facing Your Fears - School Based, Usual Care
- Behavioral
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 8 Years to 14 Years
- Enrollment
- 389 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Dapagliflozin, Placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 631 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 34
- States / cities
- Mesa, Arizona • Fresno, California • Greenbrae, California + 29 more
- Conditions
- Nonsmall Cell Lung Cancer
- Interventions
- HS-10296
- Drug
- Lead sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 364 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 10
- States / cities
- Anaheim, California • Beverly Hills, California • San Diego, California + 7 more
- Conditions
- Asthma
- Interventions
- Budesonide/albuterol sulfate metered-dose inhaler 160/180 μg, Budesonide/albuterol sulfate metered-dose inhaler 80/180 μg, Albuterol sulfate metered-dose inhaler 180 μg
- Combination Product · Drug
- Lead sponsor
- Bond Avillion 2 Development LP
- Industry
- Eligibility
- 4 Years and older
- Enrollment
- 3,132 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 170
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 139 more
- Conditions
- Multiple Sclerosis, Relapsing-Remitting
- Interventions
- Ocrelizumab
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 1,225 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 26
- States / cities
- Irvine, California • Sunnyvale, California • Aurora, Colorado + 23 more
- Conditions
- Acute Myeloid Leukemia
- Interventions
- PF-04449913, Low dose ARA-C (LDAC), Decitabine, Daunorubicin, Cytarabine
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 255 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2019
- U.S. locations
- 52
- States / cities
- Birmingham, Alabama • La Jolla, California • Los Angeles, California + 19 more
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Sotatercept, Placebo
- Drug · Other
- Lead sponsor
- Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 173 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 26
- States / cities
- Phoenix, Arizona • Los Angeles, California • Orange, California + 22 more
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- MVA-BN-RSV vaccine, Tris Buffered Saline (TBS)
- Biological
- Lead sponsor
- Bavarian Nordic
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 20,419 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 105
- States / cities
- Athens, Alabama • Birmingham, Alabama • Huntsville, Alabama + 86 more
- Conditions
- Advanced Malignant Solid Neoplasm, Recurrent Childhood Ependymoma, Recurrent Ewing Sarcoma, Recurrent Glioma, Recurrent Hepatoblastoma, Recurrent Kidney Wilms Tumor, Recurrent Langerhans Cell Histiocytosis, Recurrent Malignant Germ Cell Tumor, Recurrent Malignant Glioma, Recurrent Medulloblastoma, Recurrent Neuroblastoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Osteosarcoma, Recurrent Peripheral Primitive Neuroectodermal Tumor, Recurrent Rhabdoid Tumor, Recurrent Rhabdomyosarcoma, Recurrent Soft Tissue Sarcoma, Refractory Ependymoma, Refractory Ewing Sarcoma, Refractory Glioma, Refractory Hepatoblastoma, Refractory Langerhans Cell Histiocytosis, Refractory Malignant Germ Cell Tumor, Refractory Malignant Glioma, Refractory Medulloblastoma, Refractory Neuroblastoma, Refractory Non-Hodgkin Lymphoma, Refractory Osteosarcoma, Refractory Peripheral Primitive Neuroectodermal Tumor, Refractory Rhabdoid Tumor, Refractory Rhabdomyosarcoma, Refractory Soft Tissue Sarcoma
- Interventions
- Laboratory Biomarker Analysis, Palbociclib, Pharmacological Study
- Other · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 12 Months to 21 Years
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 115
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 93 more
- Conditions
- Uterine Neoplasms, Uterine Cervical Neoplasms, Biliary Tract Neoplasms, Urologic Neoplasms, Carcinoma, Non-Small-Cell Lung, HER2 Mutations Breast Neoplasms
- Interventions
- tucatinib, trastuzumab, fulvestrant
- Drug
- Lead sponsor
- Seagen, a wholly owned subsidiary of Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 217 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 76
- States / cities
- Phoenix, Arizona • Tempe, Arizona • Tucson, Arizona + 47 more